TY - JOUR T1 - EMA reviews bleeding risk with direct oral anticoagulants JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 88 LP - 88 DO - 10.1136/dtb.2019.000031 VL - 57 IS - 6 A2 - , Y1 - 2019/06/01 UR - http://dtb.bmj.com/content/57/6/88.abstract N2 - Review of: EU Pharmacoepidemiology and Pharmacovigilance Research Network. Characterising the risk of major bleeding in patients with non-valvular atrial fibrillation: non-interventional study of patients taking direct oral anticoagulants in the EU.Key learning pointsThe European Medicines Agency is reviewing the results of an observational study that analysed bleeding risks in patients taking direct oral anticoagulants (DOACs).The study highlighted differences in the risk of major bleeding between DOACs.Results from a European Medicines Agency (EMA) study of direct oral anticoagulants (DOACs) highlighted differences in the risk of major bleeding between these medicines and raised concerns about adherence to restrictions, special warnings and precautions in the medicines’ product information.The EMA has started a review of the results from an observational study characterising bleeding risk in patients with non-valvular atrial … ER -